用于肿瘤治疗的生物素化壳聚糖表面修饰聚乳酸-羟基乙酸共聚物纳米粒的毒性、药代动力学及体内疗效
Toxicity, pharmacokinetics, and in vivo efficacy of biotinylated chitosan surface-modified PLGA nanoparticles for tumor therapy.
作者信息
Chen Hongli, Nan WenBin, Wei Xiangjuan, Wang Yan, Lv Feng, Tang Hongbo, Li Yonghai, Zhou Chenyan, Lin Juntang, Zhu Wuling, Zhang Qiqing
机构信息
a Research Center of Stem Cell and Biotherapy Technology, School of Life Science and Technology , Xinxiang Medical University , Xinxiang , China.
b Institute of Biomedical Engineering , Chinese Academy of Medical Sciences , Tianjin , China.
出版信息
Artif Cells Nanomed Biotechnol. 2017 Sep;45(6):1-8. doi: 10.1080/21691401.2016.1202260. Epub 2016 Jun 30.
Based on our previous work on the PLGA nanoparticles modified with biotinylated chitosan (Bio-CS-PLGA NPs), we further studied the stability, toxicity, pharmacokinetics, and in vivo efficacy. The safety of NPs was studied through single-dose toxicity test in mice, and the result showed that NPs were well tolerated at the dose of 300 mg/kg. Compared with the free EPB group, the NPs group exhibited higher plasma drug concentration, longer half-life time. EPB-loaded NPs significantly inhibited the tumor growth compared to free EPB. All results suggested that Bio-CS-PLGA NPs were stable, safe, and showed a promising potential on targeted drug delivery.
基于我们之前对生物素化壳聚糖修饰的聚乳酸-羟基乙酸共聚物纳米粒（Bio-CS-PLGA NPs）的研究工作，我们进一步研究了其稳定性、毒性、药代动力学和体内疗效。通过小鼠单剂量毒性试验研究了纳米粒的安全性，结果表明在300 mg/kg剂量下纳米粒耐受性良好。与游离EPB组相比，纳米粒组表现出更高的血浆药物浓度和更长的半衰期。与游离EPB相比，载有EPB的纳米粒显著抑制肿瘤生长。所有结果表明，Bio-CS-PLGA NPs稳定、安全，在靶向药物递送方面显示出有前景的潜力。
Zotero 插件